PTC Therapeutics (PTCT) calls active on FDA approval of Sarepta's (SRPT) eteplirsen

September 19, 2016 10:19 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

PTC Therapeutics (NASDAQ: PTCT) whose Translarna drug seeks to treat nonsense mutation Duchenne muscular dystrophy is recently up 15%, after the FDA granted accelerated approval to Sarepta's (SRPT) eteplirsen, the company's treatment of Duchenne muscular dystrophy. PTCT October 11 and 12 calls are active on total call volume of 805 contracts (134 puts).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

srpt

Add Your Comment